Seponering af antitrombotisk behandling efter patenteret foramen ovale lukning hos unge patienter med kryptogent slagtilfælde (HALTI)
Seponering af antitrombotisk behandling efter patenteret Foramen Ovale lukning hos unge patienter med kryptogent slagtilfælde. HALTI-processen
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.
Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Melanie Cote, MSc
- Telefonnummer: 14186537270
- E-mail: melanie.cote@criucpq.ulaval.ca
Undersøgelse Kontakt Backup
- Navn: Josep Rodes-Cabau, MD
- Telefonnummer: 4186568711
- E-mail: josep.rodes@criucpq.ulaval.ca
Studiesteder
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Rekruttering
- IUCPQ
-
Kontakt:
- Melanie Cote, MSc
- Telefonnummer: Rodes-Cabau 4186568711
- E-mail: josep.rodes@criucpq.ulaval.ca
-
Kontakt:
- Josep Rodes-Cabau, MD
- Telefonnummer: 4186568711
- E-mail: josep.rodes@criucpq.ulaval.ca
-
Ledende efterforsker:
- Josep Rodes-Cabau, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Successful transcatheter PFO closure with any approved device
- Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure
Exclusion Criteria:
->60 year-old
- RoPE score <6
- Residual shunt ≥moderate following PFO closure
- Atrial fibrillation following PFO closure
- Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
- Diabetes mellitus
- Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
- Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
- Failure to provide signed informed consent
- Absolute contraindications for an MRI study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Antiplatelet treatment discontinuation
At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Presence of new stroke events
Tidsramme: 12 months
|
1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR < 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death. |
12 months
|
|
Presence of new ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of new cerebral ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Volume of new cerebral ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Number of ischemic events
Tidsramme: 24-month follow-up
|
Stroke, TIA |
24-month follow-up
|
|
Number of ischemic events
Tidsramme: 3-year follow-up
|
Stroke, TIA |
3-year follow-up
|
|
Number of ischemic events
Tidsramme: 4-year follow-up
|
Stroke, TIA |
4-year follow-up
|
|
Number of ischemic events
Tidsramme: 5-year follow-up
|
Stroke, TIA |
5-year follow-up
|
|
Number of ischemic events
Tidsramme: 6-year follow-up
|
Stroke, TIA |
6-year follow-up
|
|
Number of ischemic events
Tidsramme: 7-year follow-up
|
Stroke, TIA |
7-year follow-up
|
|
Number of ischemic events
Tidsramme: 8-year follow-up
|
Stroke, TIA |
8-year follow-up
|
|
Number of ischemic events
Tidsramme: 9-year follow-up
|
Stroke, TIA |
9-year follow-up
|
|
Number of ischemic events
Tidsramme: 10-year follow-up
|
Stroke, TIA |
10-year follow-up
|
|
Rate of bleeding
Tidsramme: 24-month follow-up
|
Life-threatening, major or minor bleeding |
24-month follow-up
|
|
Rate of bleeding
Tidsramme: 3-year follow-up
|
Life-threatening, major or minor bleeding |
3-year follow-up
|
|
Rate of bleeding
Tidsramme: 4-year follow-up
|
Life-threatening, major or minor bleeding |
4-year follow-up
|
|
Rate of bleeding
Tidsramme: 5-year follow-up
|
Life-threatening, major or minor bleeding |
5-year follow-up
|
|
Rate of bleeding
Tidsramme: 6-year follow-up
|
Life-threatening, major or minor bleeding |
6-year follow-up
|
|
Rate of bleeding
Tidsramme: 7-year follow-up
|
Life-threatening, major or minor bleeding |
7-year follow-up
|
|
Rate of bleeding
Tidsramme: 8-year follow-up
|
Life-threatening, major or minor bleeding |
8-year follow-up
|
|
Rate of bleeding
Tidsramme: 9-year follow-up
|
Life-threatening, major or minor bleeding |
9-year follow-up
|
|
Rate of bleeding
Tidsramme: 10-year follow-up
|
Life-threatening, major or minor bleeding |
10-year follow-up
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Hjertesygdomme
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hjertefejl, medfødt
- Slag
- Hjerteseptumdefekter, atriel
- Hjerteseptumdefekter
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Iskæmisk slagtilfælde
- Blødning
- Foramen Ovale, Patent
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HALTI
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .